This is a phase 3, multicenter, open-label, blinded, crossover trial in which each participant will undergo a randomized sequence of ASI-02 and agitated saline standard of care (SoC) via a saline contrast transthoracic echocardiogram (TTE) study.
The primary objective is to determine the safety of ASI-02 and its agreement with agitated saline SoC for detection of right-to-left shunt in saline contrast studies utilizing TTE in the intended setting of use (opacifying the right heart). The investigation will be conducted in up to 8 investigational sites in the U.S. and Canada. Participants will receive n=2 ASI-02, n=4 agitated saline SoC injections as part of a single-day imaging session, with the overall duration for study participation of 24 to 48 hours.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
300
The recommended initial dose of agitated saline SoC is approximately 10 mL of saline containing approximately 1 mL of air, per institutional policy, rapidly mixed (approximately 10-20 presses) to manufacture microbubbles. No additives are allowed to the saline, including blood, dextrose, or bacteriostatic saline.
Each injection shall utilize one (1) ASI-02 product connected to one (1) pre-filled 10 mL 0.9% sodium chloride (saline) syringe. The ASI-02 investigational product will be connected to a standard luer lock connector and administered in its entirety. The intravenous bolus injected dose of ASI-02 is 9 mL of saline and 1 mL of air.
Northwestern University
Chicago, Illinois, United States
RECRUITINGMayo Clinic
Rochester, Minnesota, United States
RECRUITINGJackson Heart Clinic
Jackson, Mississippi, United States
RECRUITINGPositive percentage agreement (PPA) of ASI-02 for detecting right-to-left shunt versus agitated saline SoC
Time frame: Procedure through 24- to 48-hour participant follow-up visit
Negative percentage agreement (NPA) of ASI-02 for detecting right-to-left shunt versus agitated saline SoC
Time frame: Procedure through 24- to 48-hour participant follow-up visit
The incidence of ASI-02-related adverse events
Time frame: 24- to 48-hour participant follow-up visit
Peak opacification intensity
Time frame: Procedure through 24- to 48-hour participant follow-up visit
Contrast opacification duration
Time frame: Procedure through 24- to 48-hour participant follow-up visit
Positive percentage agreement (PPA) of ASI-02 for shunt detection at rest
Time frame: Procedure through 24- to 48-hour participant follow-up visit
Negative percentage agreement (NPA) of ASI-02 for shunt detection at rest
Time frame: Procedure through 24- to 48-hour participant follow-up visit
Positive percentage agreement (PPA) of ASI-02 for shunt detection specific to shunt sizes
Time frame: Procedure through 24- to 48-hour participant follow-up visit
Negative percentage agreement (NPA) of ASI-02 for shunt detection specific to shunt sizes
Time frame: Procedure through 24- to 48-hour participant follow-up visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
NYU Langone Health
New York, New York, United States
RECRUITINGToronto General
Toronto, Canada
RECRUITINGTest-retest reliability of agitated saline SoC
Time frame: Procedure through 24- to 48-hour participant follow-up visit
Positive percentage agreement (PPA) of ASI-02 for detecting right-to-left shunt versus agitated saline SoC, using the first (nonrandomized) SoC study.
Time frame: Procedure through 24- to 48-hour participant follow-up visit
Negative percentage agreement (NPA) of ASI-02 for detecting right-to-left shunt versus agitated saline SoC, using the first (nonrandomized) SoC study.
Time frame: Procedure through 24- to 48-hour participant follow-up visit